(MENAFN- Gulf Times) A Qatar-based study involving 121,700 patients has underscored the importance of the post-vaccination monitoring to optimise vaccine administration and ensure patient safety.
The study by a group of researchers from Hamad Medical Hospital, Primary Health Care Corporation and Qatar University is titled 'Adverse events of Covid-19 vaccines: Insights from primary health care centres in Qatar' and was published recently in the Qatar Journal of Public Health and featured on the Qscience.
The study emphasises the need for comprehensive surveillance and analysis of vaccine safety especially in the context of Covid-19 pandemic and the subsequent efforts at vaccination of the population globally.
The research highlights the significant role of vaccination in curbing the spread of the virus and mitigating severe outcomes especially in the context of Covid-19. It also points to the swift development and deployment of Covid-19 vaccines which raised concerns about potential adverse events, underscoring the importance of the need for complete monitoring and deeper analysis of vaccine safety.
The research compares the prevalence and types of adverse events reported following the administration of different Covid-19 vaccines such as AstraZeneca, Moderna, Pfizer, Pfizer Paediatric across various doses. The objective was to delineate patterns in both local and systemic symptoms, including severe reactions such as anaphylaxis, to enhance understanding of the safety profiles of these vaccines.
The study included 121,700 patients, of whom 28,715 (23.6%) reported at least one adverse event following vaccination. According to the findings, Moderna exhibited the highest prevalence of any symptoms after the second dose (34.3%), while AstraZeneca demonstrated a significant increase in symptoms after the third dose (96.9%). Injection site pain was most prevalent with AstraZeneca's third dose (57.1%), and anaphylaxis was most commonly reported with Pfizer Paediatric's first dose (0.9%). The Pfizer Paediatric vaccine had the lowest rates of symptoms after the third dose (0.5%). Systemic symptoms, including fever and fatigue, were frequently reported across all vaccines.
The researchers conducted a retrospective analysis of Electronic Health Records from Qatar's Primary Health Care Corporation, focusing on individuals aged six months and older. Adverse event data were gathered using the“Covid-19 Post Vaccine Assessment Form,” which captures both local and systemic symptoms. Data were analysed using IBM SPSS Statistics for Windows, with frequencies and percentages summarised.
According to the researchers, the study reveals significant variability in adverse event profiles among different Covid-19 vaccines and doses.
Moderna and AstraZeneca showed higher rates of both local and systemic symptoms, with AstraZeneca's third dose exhibiting the highest overall symptom prevalence. Pfizer Paediatric had lower adverse event rates, though anaphylaxis and systemic symptoms like fever were more notable after the first dose.
The study has concluded that the findings emphasise the importance of ongoing post-vaccination monitoring to optimise vaccine administration and ensure patient safety.

MENAFN11072025000067011011ID1109790929